Spravato is a form of esketamine that patients take as a self-administered ... Esketamine is available through the Risk ...
Credit: Johnson & Johnson. The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, placebo-controlled, phase 4 TRD4005 trial.
The FDA has approved Spravato (esketamine) nasal spray for use as monotherapy for patients with treatment-resistant depression.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback